Amanda Compadre, MD, and Lily van Biljon recently published an article in Clinical Cancer Research titled “RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.” This paper demonstrates that RAD51 foci are a robust marker of platinum chemotherapy response and survival in ovarian cancer. This research was led by Mary (Maggie) Mullen, MD.
Read their original work: https://aacrjournals.org/clincancerres/article-lookup/doi/10.1158/1078-0432.CCR-22-3335